Cyclooxygenase 2: From Inflammation to Carcinogenesis
- Derek J. Chadwick Organizer,
- Jamie A. Goode
Published Online: 7 OCT 2008
DOI: 10.1002/0470856734.ch16
Copyright © Novartis Foundation 2004
Book Title

Cancer and Inflammation: Novartis Foundation Symposium 256
Additional Information
How to Cite
Ristimäki, A. (2008) Cyclooxygenase 2: From Inflammation to Carcinogenesis, in Cancer and Inflammation: Novartis Foundation Symposium 256 (eds D. J. Chadwick and J. A. Goode), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/0470856734.ch16
Publication History
- Published Online: 7 OCT 2008
- Published Print: 23 JAN 2004
ISBN Information
Print ISBN: 9780470855102
Online ISBN: 9780470856734
- Summary
- Chapter
Summary
Cyclooxygenase (COX) is the rate-limiting enzyme in the conversion of arachidonic acid to prostanoids. Two COX isoforms have been cloned, of which COX-1 is constitutively expressed, while the expression of COX-2 is low or nondetectable in most tissues, but can be readily induced in response to cell activation by cytokines, growth factors and tumour promoters. Thus, COX-1 is considered a housekeeping gene and thought to be responsible for the synthesis of prostanoids involved in cytoprotection of the stomach and for the production of the pro-aggregatory prostanoid thromboxane by the platelets. In contrast, COX-2 is an inducible, immediate-early gene, and its role has been related to inflammation, reproduction and carcinogenesis. Expression of COX-2 is elevated in a variety of human malignancies and in their precursor lesions. Furthermore, genetic deletion or pharmacological inhibition of COX-2 suppresses tumour growth in several animal models of carcinogenesis. In humans, elevated COX-2 expression is associated with poor prognosis in adenocarcinomas of the digestive tract and the breast, and a selective inhibitor of COX-2 reduced polyp burden in patients who suffer from familial adenomatous polyposis. Thus, COX-2 seems to be a relevant target in chemoprevention.
